Hisamitsu Pharma
Japanese drugmaker Hisamitsu Pharmaceutical’s (TYO: 4530) has announced the results of a Phase II clinical study for a transdermal drug for the treatment of Parkinson’s disease in Japan

The efficacy and safety of the HP-3000 (ropinirole hydrochloride) were compared with a placebo in patients with Parkinson’s disease who concomitantly used L-dopa (levodopa). A statistically significant difference was confirmed for improvement in the primary efficacy endpoint compared with the placebo group.

The product is a transdermal formulation developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology. Hisamitsu aims to initiate a Phase III clinical study later this year.

A company statement said: “We expect the product to be a new option for the treatment of Parkinson’s disease by realizing its long-lasting effect by means of maintaining a stable blood concentration.”

A Phase II clinical study of the product started last year for moderate to severe idiopathic restless leg syndrome.

Hisamitsu, Parkinson’s disease, HP-3000